Lexaria Bioscience Warrant (LEXXW) last traded on January 13, 2026, and the SEC no longer lists LEXXW among current company tickers.
Price Move History
- Daily moves over 5%
- 124 182 sessions, January 13, 2025 to January 13, 2026
- Largest daily move
- +116.7% close of January 2, 2026
- 1-year change
- -99.8% closing prices, January 13, 2025 to January 13, 2026
- 1-month change
- -95.7% closing prices, December 12, 2025 to January 13, 2026
Company Description
Written before these shares stopped trading.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) is described in its public communications as a global innovator in drug delivery platforms. The company focuses on its patented DehydraTECH™ formulation and processing platform technology, which is designed to improve the way a variety of drugs enter the bloodstream through oral delivery. According to multiple company news releases, DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood brain barrier.
Lexaria operates within the pharmaceutical and biotechnology ecosystem while being classified under medicinal and botanical manufacturing in the manufacturing sector. Its business activities, as outlined in press releases, center on research and development of DehydraTECH-enabled formulations, clinical and pre-clinical studies, and the pursuit of licensing and partnering opportunities with pharmaceutical and biotechnology companies. The company also operates a licensed in-house research laboratory and reports holding an intellectual property portfolio with more than 50 granted patents worldwide, with additional patents pending.
DehydraTECH Platform and Drug Delivery Focus
The core of Lexaria’s business model is its DehydraTECH drug delivery platform. Company disclosures state that DehydraTECH is a patented formulation and processing technology intended to improve oral delivery of drugs. Public statements emphasize three main attributes of the platform:
- Increasing bio-absorption of active pharmaceutical ingredients.
- Reducing side effects, including gastrointestinal adverse events in certain studies.
- Enhancing delivery of some drugs across the blood brain barrier.
Lexaria’s communications highlight that DehydraTECH is applied to a range of drug types. The company has reported work with glucagon-like peptide‑1 (GLP‑1) drugs such as semaglutide, tirzepatide, and liraglutide, as well as cannabidiol (CBD). These efforts are directed at oral delivery formats and are being evaluated in both human and animal studies.
Clinical and Pre-Clinical Programs
Based on recent news, Lexaria dedicates significant resources to research and development programs that evaluate DehydraTECH with established drugs. The company has described multiple human clinical studies and pre-clinical work, including:
- Human Pilot Studies involving GLP‑1 drugs such as tirzepatide and liraglutide, comparing DehydraTECH-processed oral formulations to injectable reference products.
- Phase 1b Study GLP‑1‑H24‑4 in Australia, a registered 12‑week chronic study with follow-up, which investigated several DehydraTECH formulations (including DehydraTECH‑CBD, DehydraTECH‑semaglutide, and DehydraTECH‑tirzepatide) relative to the oral GLP‑1 product Rybelsus® as a control.
- Rodent biodistribution studies using fluorescently tagged semaglutide to compare DehydraTECH‑processed compositions with conventional oral formulations.
Company-reported outcomes from these studies emphasize safety and tolerability of DehydraTECH formulations, reductions in total and gastrointestinal adverse events relative to control arms, and comparable performance on key efficacy parameters such as blood glucose, insulin, and certain body composition measures in defined settings. Lexaria also reports exploratory findings related to blood pressure reductions in a DehydraTECH‑CBD arm and brain biodistribution trends in animal studies.
Therapeutic Areas and R&D Priorities
In strategic updates, Lexaria identifies several therapeutic areas where DehydraTECH-based formulations are being explored or protected by patents. These include:
- Diabetes control and weight loss, particularly through GLP‑1 drug formulations.
- Hypertension, including a program to investigate DehydraTECH‑CBD for blood pressure reduction.
- Seizure disorders.
- Anti-viral applications.
- Hormone replacement and other pharmaceutical applications.
The company notes that its patents cover compositions and methods for treating conditions such as epilepsy, diabetes, hypertension, and viral infections, as well as food and beverage compositions infused with lipophilic active agents. These disclosures indicate that Lexaria views DehydraTECH as a broad platform technology with potential applicability across multiple therapeutic categories, even though the development stage and regulatory status of individual programs vary.
Intellectual Property and Patents
Lexaria consistently highlights its intellectual property position as a key asset. In various news releases, the company reports holding more than 50 granted patents worldwide, with specific counts (such as 50, 54, or 56) cited at different times as new patents are issued. Recent patent grants mentioned include:
- Patents for compositions and methods for treating epilepsy.
- Patents for compositions and methods for treating diabetes.
- Patents covering food and beverage compositions infused with lipophilic active agents.
- Patents for enhanced delivery of antiviral agents.
These patents are part of broader patent families that, according to Lexaria, support its strategy of building long-term value around DehydraTECH-enabled formulations and potential licensing or partnering arrangements.
Partnerships and Material Transfer Agreement
Lexaria has disclosed a Material Transfer Agreement (MTA) with a pharmaceutical company, referred to as "PharmaCo," to evaluate DehydraTECH in a pre-clinical setting. The company reports that:
- The MTA was originally entered into in 2024 and later extended through April 30, 2026.
- Initial pre-clinical pharmacokinetic studies under the MTA were completed.
- PharmaCo requested access to the full dataset from Lexaria’s Australian human clinical study GLP‑1‑H24‑4 for review.
Lexaria characterizes the MTA as including a temporary exclusive license and as a framework for potential additional strategic planning discussions with PharmaCo’s human clinical development team. The outcome of these discussions is not specified in the available information, but the extension of the MTA indicates an ongoing evaluation relationship.
Capital Markets Activity and Use of Proceeds
Lexaria Bioscience Corp. is listed on Nasdaq under the symbols LEXX (common shares) and LEXXW (warrants). Company news releases describe several registered direct offerings of common stock, often accompanied by concurrent private placements of unregistered warrants. These financings are described as being priced at-the-market under Nasdaq rules.
Across multiple announcements, Lexaria states that the gross proceeds from these offerings are intended to be used to advance its research and development efforts, fund working capital, and support other general corporate purposes. In some cases, the company notes that the additional capital is expected to enable R&D and business development programs into future periods, including new or expanded clinical and pre-clinical work in the GLP‑1 sector and other areas of interest.
Business Development and Strategic Outreach
In a strategic update, Lexaria reports engaging a global life science business development advisory firm to support new business development activities. The company indicates that this engagement is intended to:
- Identify and pursue collaborative business opportunities with pharmaceutical and biotechnology companies.
- Expand outreach related to licensing and partnering discussions around DehydraTECH.
Lexaria notes that, due to the sensitive nature of such discussions, specific counterparties are not named. The company links this expanded outreach to its recently completed equity financings, which it states provide resources to support both business development and R&D expansion.
Role in the Medicinal and Botanical Manufacturing Sector
Within the broader medicinal and botanical manufacturing industry, Lexaria positions itself, through its public statements, as a technology-focused company centered on oral drug delivery improvement rather than on traditional bulk manufacturing of active ingredients. Its emphasis on platform technology, intellectual property, and clinical data suggests a model where value is built around DehydraTECH-enabled formulations and potential collaborations with larger pharmaceutical entities.
For investors and observers, the key elements described by the company include its Nasdaq listing (LEXX and LEXXW), its DehydraTECH drug delivery platform, its ongoing clinical and pre-clinical programs in areas such as GLP‑1 drugs and CBD, its patent portfolio, and its efforts to secure partnerships and funding to support further development.
Stock Performance
Lexaria Bioscience Warrant (LEXXW) closed at $0.0012 on January 13, 2026. In the 12 months to January 13, 2026, the price lost 99.8%.
See what a $1,000 investment in LEXXW was worth at its last close
LEXXW Metrics & Rankings
Price returns through January 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Lexaria Bioscience Warrant has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 1 with negative movement. Key topics include clinical trial. View all LEXXW news →
SEC Filings
Lexaria Bioscience Warrant has filed 8 recent SEC filings, including 5 Form 4, 2 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LEXXW SEC filings →
Financial Highlights
Lexaria Bioscience Warrant generated $706K in revenue in FY2025, retaining a 99.6% gross margin, operating income reached -$11.9M, and net income was -$11.9M. Diluted earnings per share stood at -$0.66. The company generated -$10.5M in operating cash flow. The current ratio was 2.32, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Lexaria Bioscience Warrant (LEXXW) currently stands at 1.9 thousand shares, up 30.0% from the previous reporting period. Since November 2025, short interest has increased by 21.8%.
Days to Cover History
Days to cover for Lexaria Bioscience Warrant (LEXXW) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.
LEXXW Company Profile & Sector Positioning
Lexaria Bioscience Warrant (LEXXW) .
Investors comparing LEXXW often look at related companies in the same sector, including Eupraxia Pharmaceuticals Inc. (EPRX), CAMP4 Therapeutics Corporation (CAMP), Dogwood Therapeutics, Inc. (DWTX), Veru Inc. (VERU), and Alzamend Neuro, Inc. (ALZN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate LEXXW's relative position within its industry.